Flutiform filing referred to EMA for arbitration
This article was originally published in Scrip
The decentralised procedure application for approval of SkyePharma's combination asthma treatment Flutiform (fluticasone propionate plus formoterol fumarate) has been referred to the European Medicines Agency for arbitration, after the reference member state (RMS) and concerned member states (CMSs) could not reach consensus over its approvability.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.